Related Experiment Video
Updated: Jun 1, 2026
06:26
Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
Published on: July 28, 2023
The challenges of developing new tuberculosis vaccines
Lewellys F Barker1, Annmarie E Leadman, Bartholt Clagett
1Aeras, Rockville, Maryland, USA.lbarker@aeras.org
Health Affairs (Project Hope)
|June 10, 2011
Summary
Developing a new tuberculosis vaccine is crucial as the current one fails to protect adults, who drive the epidemic. Collaboration is key to overcoming scientific and policy hurdles for a life-saving vaccine.
Area of Science:
- Global Health
- Vaccinology
- Infectious Diseases
Background:
- Tuberculosis (TB) causes nearly two million deaths annually, predominantly in developing nations.
- The current TB vaccine is ineffective in preventing disease in adults, the primary drivers of the epidemic.
- Existing vaccination strategies are insufficient for controlling adult TB transmission.
Purpose of the Study:
- To highlight the urgent need for a new tuberculosis vaccine.
- To identify the scientific and policy challenges in developing novel TB vaccines.
- To emphasize the importance of collaborative efforts in vaccine development.
Main Methods:
- Review of current global tuberculosis statistics and vaccine efficacy.
- Analysis of challenges in tuberculosis vaccine research and development.
- Examination of policy and resource-related obstacles.
Main Results:
- The current BCG vaccine offers limited protection against adult tuberculosis.
- Several new tuberculosis vaccine candidates are progressing through clinical trials.
- Significant scientific, policy, and resource challenges impede vaccine development.
Conclusions:
- A new tuberculosis vaccine is urgently needed to combat the adult-driven epidemic.
- Overcoming scientific and policy challenges requires a collaborative approach.
- Partnerships between emerging economies and vaccine organizations are vital for public health impact.
More Related Videos
Related Concept Videos
01:23Tuberculosis
Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:28Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...